ACE2, TMPRSS2, Acute Lung Injury, ARDS, and Lung Fibrosis

June 19, 2020COVID-19, Vizit Graphs

The graph visualizes the relationships between genes ACE2 and TMPRSS2 and specific manifestations of COVID-19, such as Acute Lung Injury, ARDS and Lung Fibrosis through a network of specific biological entities such as Cell Types, Pathways and Anatomical Locations that are likely implicated in the pathogenesis of these disease symptoms. Explore the live graph.

Repositioning Safety

May 22, 2020Blog

There is an urgent need for the healthcare industry to reposition safety: that is to change how the ability to discover, possess information about and act on predicted Adverse Drug Reactions (ADR) is perceived and treated by pharma companies, the regulator and other stakeholders.  To date drug testing has been biased toward minimizing “Type I” … Read More

Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19

April 22, 2020Press Releases

CHARLOTTESVILLE, Va., April 22, 2020 /PRNewswire/ — Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds — to counter key symptoms of COVID-19. “Drug AI helps find that needle in the haystack, and we are optimistic that we have found four … Read More

Business Development Agent in Japan

February 12, 2020Announcements

Biovista is pleased to announce the appointment of a Business Development Agent in Japan. Based in Tokyo, our BD Agent will serve Biovista customers and collaborators throughout Japan. Our agent will focus on Biovista’s new therapy development services and will serve as the main contact point for our Japanese customers. Additionally, our Agent will support … Read More